Biotechnology News and Research

RSS

pSivida reports revenues of $699,000 for fourth quarter 2012

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2012.

25 Sep 2012

RXi completes dosing in RXI-109 Phase 1 study for dermal scarring

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that dosing with their first drug in its first Phase 1 study, was completed last week.

24 Sep 2012

Researchers identify subgroups of B cells in MYC-positive germinal centers

Germinal centers are sites in the organs of the lymphatic system, formed during the course of an immune response to infection, where B cells intensely proliferate and modify their DNA in order to produce antibodies specific for the pathogen. However, it is known that the vast majority of lymphomas derive from the B cells at the germinal centers.

24 Sep 2012

Strand Life Sciences to validate and commercialize Trovagene's urine-based HPV test

Trovagene, Inc. and Strand Life Sciences Pvt Ltd., of Bangalore, India, completed their agreement to validate and commercialize Trovagene's proprietary urine-based Human Papillomavirus (HPV) test for clinical diagnostic and carrier screening use.

21 Sep 2012

Isolating and concentrating cells from whole blood: an interview with Victor Ugaz

There are several reasons for this. One is because analysis involving different kinds of blood cells may require you to be able to separate red blood cells from white blood cells, or plasma from whole blood etc.

21 Sep 2012

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today reported milestone achievements advancing BiovaxID, Biovest's personalized cancer vaccine for the treatment of non-Hodgkin's lymphoma, including a recently conducted regulatory meeting with the European Medicines Agency (EMA) and the appointment of a key contributor to the Human Genome Project to its Scientific Advisory Board.

21 Sep 2012

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.

21 Sep 2012

PNAS: Ras proteins bring tension to the phosphate chain

Proteins accelerate certain chemical reactions in cells by several orders of magnitude. The molecular mechanism by which the Ras protein accelerates the cleavage of the molecule GTP and thus slows cell growth is described by biophysicists at the Ruhr-Universit-t Bochum led by Prof. Dr. Klaus Gerwert in the Online Early Edition of the journal PNAS.

20 Sep 2012

AyoxxA Biosystems closes 2.6M Euro Series A financing round

AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten, both formerly executive board members and co-founders of amaxa biosystems.

20 Sep 2012

Thermo Fisher Scientific announces opening of Molecular Biology Center of Excellence in Lithuania

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the official opening of its Molecular Biology Center of Excellence in Vilnius, Lithuania.

From Thermo Fisher Scientific Inc. 20 Sep 2012

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Gamida Cell, a leader in adult stem cell expansion technologies and products, announced today that it has completed enrollment for a Phase I/II clinical trial of NiCord, the company's second pipeline product.

20 Sep 2012

Better interventions needed to prevent long-lasting consequences of TBI in children

A child who suffers a moderate or severe traumatic brain injury (TBI) may still have substantial functional disabilities and reduced quality of life 2 years after the injury. After those first 2 years, further improvement may be minimal. Better interventions are needed to prevent long-lasting consequences of TBI in children conclude the authors of a study published in Journal of Neurotrauma, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

19 Sep 2012

Rainbow Biosciences explores NASA technology to produce adult stem cells for medical research

Rainbow Biosciences, the biotech subsidiary of Rainbow Coral Corp., announced today that it is exploring the possible use of micro-gravity technology developed by NASA to produce three-dimensional adult stem cells for medical research purposes.

19 Sep 2012

ChanTest announces Phase II SBIR grant to optimize cardiomyocyte-based assays

ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant. ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes

18 Sep 2012

ProImmune launches ProStorm in vitro cytokine release assay

ProImmune Ltd., a leader in services for understanding immune responses, announced today the commercial launch of ProStorm, an in vitro cytokine release assay, which can help assess the likelihood of first infusion reactions to novel therapeutics.

18 Sep 2012

Researchers to probe causes, treatments of toxic reactions in blood plasma

In the largest undertaking of its kind, scientists at four leading U.S. research institutions are embarking upon a five-year National Institutes of Health (NIH)-funded study to make blood transfusions safer and more effective by uncovering the exact causes of hemoglobin toxicity.

18 Sep 2012

Scripps Florida scientist receives two grants to focus on sulfenylation

A scientist from the Florida campus of The Scripps Research Institute has been awarded a pair of grants totaling $2.8 million from the National Institute of General Medical Sciences of the National Institutes of Health, and from TargAnox, a Massachusetts-based biotechnology firm.

18 Sep 2012

Wockhardt receives FDA marketing approval for Lansoprazole

Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 15mg and 30 mg delayed release capsules of Lansoprazole, which is used in treatment of peptic ulcers. Lansoprazole is the generic name for the brand Prevacid, marketed in the United States by Takeda. Wockhardt is launching the product immediately.

17 Sep 2012

NIH awards ASC grant to study ASC-101-treated amniotic fluid-derived stem cells in compartment syndrome

America Stem Cell, Inc. today announced that it has been awarded an Advanced Technology Small Business Technology Transfer Research (STTR) grant from the National Heart Lung and Blood Institute at the National Institutes of Health.

17 Sep 2012

UK researchers team up to help improve training for elite athletes

Some of the UK's leading bioscience and sports researchers have teamed up to help improve training for elite athletes, thanks to special funding from the Biotechnology and Biological Sciences Research Council (BBSRC) and UK Sport with additional money from the Economic and Social Research Council (ESRC).

17 Sep 2012

Biotechnology News and Research

pSivida reports revenues of $699,000 for fourth quarter 2012

RXi completes dosing in RXI-109 Phase 1 study for dermal scarring

Researchers identify subgroups of B cells in MYC-positive germinal centers

Strand Life Sciences to validate and commercialize Trovagene's urine-based HPV test

Isolating and concentrating cells from whole blood: an interview with Victor Ugaz

Biovest seeks EMA approval for BiovaxID to treat non-Hodgkin's lymphoma

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

PNAS: Ras proteins bring tension to the phosphate chain

AyoxxA Biosystems closes 2.6M Euro Series A financing round

Thermo Fisher Scientific announces opening of Molecular Biology Center of Excellence in Lithuania

Enrollment complete in Gamida Cell’s NiCord Phase I/II trial for hematological malignancies

Better interventions needed to prevent long-lasting consequences of TBI in children

Rainbow Biosciences explores NASA technology to produce adult stem cells for medical research

ChanTest announces Phase II SBIR grant to optimize cardiomyocyte-based assays

ProImmune launches ProStorm in vitro cytokine release assay

Researchers to probe causes, treatments of toxic reactions in blood plasma

Scripps Florida scientist receives two grants to focus on sulfenylation

Wockhardt receives FDA marketing approval for Lansoprazole

NIH awards ASC grant to study ASC-101-treated amniotic fluid-derived stem cells in compartment syndrome

UK researchers team up to help improve training for elite athletes

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News